All PlansAdministrativeMedium impact
Voluntary nationwide recall: Brexafemme
UPMC Health Plan·OB-GYN, Family Medicine, Internal Medicine·Pharmacy
We identified it
Jun 20, 2026
Summary
Scynexis, Inc. has issued a voluntary nationwide recall of two lots of Brexafemme (ibrexafungerp tablets) due to potential cross-contamination with a nonantibacterial ß-lactam drug substance. This antifungal medication is used for treating vulvovaginal candidiasis and reducing recurrent vulvovaginal candidiasis.
Action Required
Immediately: Clinical staff should identify patients who may have received recalled Brexafemme lots and contact them per FDA recall procedures. Billing team should flag any recent claims for Brexafemme and be prepared to handle potential reimbursement adjustments if alternative treatments are prescribed. Review the full recall notice at the provided URL for specific lot numbers.